Research reveals cannabinoids reduce astrocyte glucose metabolism, impairing neuronal function and social interaction behaviors. The study identifies CB1 receptors as key players in this process.
The CheckMate -9ER trial found that combining nivolumab and cabozantinib improved progression-free survival by doubling it compared to sunitinib, with a higher response rate and superior quality of life for patients. The combination treatment demonstrated meaningful efficacy benefits and manageable toxicity.
A study published in Soil Biology and Biochemistry found that high soil moisture content can lead to increased carbon dioxide emissions due to accelerated mineralization processes. Protecting meadowlands from bogging may help reduce CO2 emissions and slow down global warming.
A UC study found that patients with cancer who contract COVID-19 have a higher risk of death if treated with certain anti-cancer therapies at specific times. The study analyzed data from over 3,000 patients and found that those treated one to three months prior to diagnosis had the highest mortality rates.
A phase 3 trial found that combining nivolumab and cabozantinib was superior to sunitinib for progression-free survival, overall survival, and response rate in patients with metastatic kidney cancer. The treatment reduced the risk of progression or death by almost 50%.